194 related articles for article (PubMed ID: 10570186)
21. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors.
Chen HX; Marshall JL; Ness E; Martin RR; Dvorchik B; Rizvi N; Marquis J; McKinlay M; Dahut W; Hawkins MJ
Clin Cancer Res; 2000 Apr; 6(4):1259-66. PubMed ID: 10778949
[TBL] [Abstract][Full Text] [Related]
22. Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models.
Zhang Z; Wang H; Prasad G; Li M; Yu D; Bonner JA; Agrawal S; Zhang R
Clin Cancer Res; 2004 Feb; 10(4):1263-73. PubMed ID: 14977824
[TBL] [Abstract][Full Text] [Related]
23. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
Tortora G; Caputo R; Damiano V; Melisi D; Bianco R; Fontanini G; Veneziani BM; De Placido S; Bianco AR; Ciardiello F
Clin Cancer Res; 2003 Apr; 9(4):1566-72. PubMed ID: 12684433
[TBL] [Abstract][Full Text] [Related]
24. Antisense protein kinase A RIalpha inhibits 7,12-dimethylbenz(a)anthracene-induction of mammary cancer: blockade at the initial phase of carcinogenesis.
Nesterova MV; Cho-Chung YS
Clin Cancer Res; 2004 Jul; 10(13):4568-77. PubMed ID: 15240549
[TBL] [Abstract][Full Text] [Related]
25. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
Wang H; Nan L; Yu D; Agrawal S; Zhang R
Clin Cancer Res; 2001 Nov; 7(11):3613-24. PubMed ID: 11705884
[TBL] [Abstract][Full Text] [Related]
26. Antisense-protein kinase A: a single-gene-based therapeutic approach.
Cho-Chung YS; Nesterova M; Kondrashin A; Noguchi K; Srivastava R; Pepe S
Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):217-23. PubMed ID: 9212914
[No Abstract] [Full Text] [Related]
27. A high-efficacy antisense RIalpha poly-DNP 21-nt RNA.
Shen L; Chen X; Wang JH
Antisense Nucleic Acid Drug Dev; 2003 Feb; 13(1):67-74. PubMed ID: 12691537
[TBL] [Abstract][Full Text] [Related]
28. Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.
Wang H; Nan L; Yu D; Lindsey JR; Agrawal S; Zhang R
Mol Med; 2002 Apr; 8(4):185-99. PubMed ID: 12149568
[TBL] [Abstract][Full Text] [Related]
29. Growth arrest and induction of apoptosis in breast cancer cells by antisense depletion of protein kinase A-RI alpha subunit: p53-independent mechanism of action.
Srivastava RK; Srivastava AR; Seth P; Agrawal S; Cho-Chung YS
Mol Cell Biochem; 1999 May; 195(1-2):25-36. PubMed ID: 10395066
[TBL] [Abstract][Full Text] [Related]
30. Cooperative antitumor effect of mixed backbone oligonucleotides targeting protein kinase A in combination with cytotoxic drugs or biologic agents.
Tortora G; Caputo R; Damiano V; Bianco R; Pepe S; Pomatico G; Bianco AR; Jiang Z; Agrawal S; Ciardiello F
Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):141-5. PubMed ID: 9593054
[No Abstract] [Full Text] [Related]
31. Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth.
Tortora G; Caputo R; Pomatico G; Pepe S; Bianco AR; Agrawal S; Mendelsohn J; Ciardiello F
Clin Cancer Res; 1999 Apr; 5(4):875-81. PubMed ID: 10213224
[TBL] [Abstract][Full Text] [Related]
32. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
Wang H; Yu D; Agrawal S; Zhang R
Prostate; 2003 Feb; 54(3):194-205. PubMed ID: 12518324
[TBL] [Abstract][Full Text] [Related]
33. Protein kinase A-Ialpha subunit-directed antisense inhibition of ovarian cancer cell growth: crosstalk with tyrosine kinase signaling pathway.
Alper O; Hacker NF; Cho-Chung YS
Oncogene; 1999 Sep; 18(35):4999-5004. PubMed ID: 10490835
[TBL] [Abstract][Full Text] [Related]
34. Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models.
Mewani RR; Tang W; Rahman A; Dritschilo A; Ahmad I; Kasid UN; Gokhale PC
Int J Oncol; 2004 May; 24(5):1181-8. PubMed ID: 15067340
[TBL] [Abstract][Full Text] [Related]
35. Antisense inhibition of methylenetetrahydrofolate reductase reduces cancer cell survival in vitro and tumor growth in vivo.
Stankova J; Shang J; Rozen R
Clin Cancer Res; 2005 Mar; 11(5):2047-52. PubMed ID: 15756031
[TBL] [Abstract][Full Text] [Related]
36. Antisense oligonucleotides targeting RI alpha subunit of protein kinase A. In vitro and in vivo anti-tumor activity and pharmacokinetics.
Zhang R; Wang H
Methods Mol Med; 2003; 75():637-54. PubMed ID: 12407769
[No Abstract] [Full Text] [Related]
37. Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A.
Ciardiello F; Caputo R; Pomatico G; De Laurentiis M; De Placido S; Bianco AR; Tortora G
Int J Cancer; 2000 Mar; 85(5):710-5. PubMed ID: 10699953
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts.
Lopes de Menezes DE; Mayer LD
Cancer Chemother Pharmacol; 2002 Jan; 49(1):57-68. PubMed ID: 11855753
[TBL] [Abstract][Full Text] [Related]
39. Growth inhibition and antimetastatic effect of antisense poly-DNP-RNA on human breast cancer cells.
Ru K; Schmitt S; James WI; Wang JH
Oncol Res; 1999; 11(11-12):505-12. PubMed ID: 10905562
[TBL] [Abstract][Full Text] [Related]
40. Synergistic growth inhibition and induction of apoptosis by a novel mixed backbone antisense oligonucleotide targeting CRIPTO in combination with C225 anti-EGFR monoclonal antibody and 8-Cl-cAMP in human GEO colon cancer cells.
Normanno N; Tortora G; De Luca A; Pomatico G; Casamassimi A; Agrawal S; Mendelsohn J; Bianco AR; Ciardiello F
Oncol Rep; 1999; 6(5):1105-9. PubMed ID: 10425310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
